Anlotinib plus tislelizumab for recurrent metastatic pancreas ductal adenocarcinoma with germline BRCA2 mutation: A case report
In conclusion, the combination of tislelizumab and anlotinib may offer a viable therapeutic option for recurrent metastatic BRCA2-mutated PDAC.PMID:38515651 | PMC:PMC10952340 | DOI:10.3892/etm.2024.12466
Source: Experimental and Therapeutic Medicine - Category: General Medicine Authors: Sujuan Peng Hongxiang Huang Xie Zhu Jinhong Chen Xinjing Ding Fen Wang Li Chen Zhihui Lu Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | CT Scan | General Medicine | Hepatocellular Carcinoma | Immunotherapy | Kidney Cancer | Liver Cancer | Lung Cancer | Non-Small Cell Lung Cancer | Pancreas | Pancreatic Cancer | PET Scan | Renal Cell Carcinoma